. 2024 Apr 16;34(10):6488–6498. doi: 10.1007/s00330-024-10652-4

Table 2.

Per-lesion and per-patient detection rate (%) of spinal bone metastases utilizing [⁶⁸Ga]DOTATATE PET/CT, [¹⁸F]FDG PET/CT, MRI of the spine, whole-body MRI, and whole-body CT in pheochromocytoma/paraganglioma participants

Detection rates	[⁶⁸ Ga]DOTATATE PET/CT	[¹⁸F]FDG PET/CT	MRI of the spine	Whole-body MRI	Whole-body CT
Per-lesion	377/382 (98.7%, 97.0–99.6%)	275/382 (72.0%, 67.2–76.4%)	308/382 (80.6%, 76.3–84.5%)	136/246 (55.3%, 48.8–61.6%)	132/295 (44.8%, 39.0–50.6%)
Per-patient	41/41 (100%, -91.4–100%)	37/41 (90.2%, 76.9–97.3%)	40/41 (97.6%, 87.1–99.9%)	22/23 (95.7%, 78.1–99.9%)	27/33 (81.8%, 64.5–93.0%)

Detection rates

[⁶⁸ Ga]DOTATATE PET/CT

[¹⁸F]FDG PET/CT

MRI of the spine

Whole-body MRI

Whole-body CT

Per-lesion

377/382

(98.7%, 97.0–99.6%)

275/382

(72.0%, 67.2–76.4%)

308/382

(80.6%, 76.3–84.5%)

136/246

(55.3%, 48.8–61.6%)

132/295

(44.8%, 39.0–50.6%)

Per-patient

41/41

(100%, -91.4–100%)

37/41

(90.2%, 76.9–97.3%)

40/41

(97.6%, 87.1–99.9%)

22/23

(95.7%, 78.1–99.9%)

27/33

(81.8%, 64.5–93.0%)

Values in the table are detection rates expressed in ratios, defined as the number of lesions or participants detected by the imaging modality compared to the total number of lesions or participants evaluated by that modality. In parentheses are the percentages along with 95% confidence intervals